Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients
暂无分享,去创建一个
[1] L. Notarangelo,et al. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity , 2021, Journal of Allergy and Clinical Immunology.
[2] K. Stiasny,et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity , 2021, Annals of the Rheumatic Diseases.
[3] M. Gaboli,et al. SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance? , 2021, Journal of Clinical Immunology.
[4] N. Freund,et al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity , 2021, Journal of Allergy and Clinical Immunology.
[5] T. Hatahet,et al. COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic? , 2021, Infectious disease reports.
[6] I. Tezcan,et al. COVID-19 in Patients with Primary Immunodeficiency , 2021, Journal of Clinical Immunology.
[7] O. Schwartz,et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2 , 2020, Science Translational Medicine.
[8] B. Lambrecht,et al. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study , 2020, Journal of Allergy and Clinical Immunology.
[9] Steven M. Holland,et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.
[10] Jacques Fellay,et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.
[11] Zhihua Zheng,et al. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients , 2020, Cell Host & Microbe.
[12] K. Fitzgerald,et al. Toll-like Receptors and the Control of Immunity , 2020, Cell.
[13] Mei-jiao Gong,et al. Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection , 2018, Cellular Physiology and Biochemistry.
[14] C. Cunningham-Rundles,et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. , 2018, The Journal of allergy and clinical immunology.
[15] D. Weissman,et al. mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.
[16] J. Tam,et al. Human Coronaviruses: A Review of Virus–Host Interactions , 2016, Diseases.
[17] J. Casanova,et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. , 2016, Blood.
[18] S. Smeekens,et al. Gain‐of‐function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC) , 2015, European journal of immunology.